Artelo Biosciences ARTL Income Statement (2014-2025)

NASDAQ ARTL
$0.71 -0.01 (-1.35%)
As of: Aug 20, 2026 · 3:54 PM EDT
Income Statement May2014 Aug2014 Nov2014 Feb2015 May2015 Aug2015 Nov2015 Feb2016 May2016 Aug2016 Nov2016 Feb2017 May2017 Aug2017 Nov2017 Feb2018 May2018 Aug2018 Nov2018 Feb2019 May2019 Aug2019 Nov2019 Feb2020 May2020 Aug2020 Nov2020 Feb2021 May2021 Aug2021 Nov2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Operating items
Depreciation & Amortization - Total (Quarter)
Research & Development (Quarter)
0.66M0.95M1.19M1.27M0.46M1.06M1.08M1.73M1.24M0.75M1.58M2.12M1.51M1.69M0.33M2.48M1.38M1.87M1.27M0.89M
Selling, General & Administrative (Quarter)
1.01M1.07M3.38M1.28M1.48M1.42M1.32M1.75M1.06M1.03M1.03M1.12M1.08M0.83M0.87M1.34M0.99M1.28M1.81M1.89M
Restructuring Costs (Quarter)
0.31M0.30M0.33M0.37M0.32M0.25M0.33M0.31M
Other Operating Expenses (Quarter)
0.20M0.23M-0.79M-0.31M-0.30M-0.33M-0.37M-0.32M-0.25M-0.33M-0.31M
Operating Expenses (Quarter)
1.87M2.25M3.78M2.55M1.95M2.47M2.39M3.48M2.29M1.78M2.61M3.24M2.59M2.51M1.20M3.81M2.38M3.15M3.09M2.79M
Operating Income (Quarter)
-1.87M-2.25M-3.78M-2.55M-1.95M-2.47M-2.39M-3.48M-2.29M-1.78M-2.61M-3.24M-2.59M-2.51M-1.20M-3.81M-2.38M-3.15M-3.09M-2.79M
EBIT (Quarter)
-1.87M-2.25M-3.78M-2.55M-1.95M-2.47M-2.39M-3.48M-2.29M-1.78M-2.61M-3.24M-2.59M-2.51M-1.20M-3.81M-2.38M-3.15M-3.09M-2.79M
Non-operating items
Non Operating Investment Income (Quarter)
0.00M984.000.07M0.14M0.12M0.18M0.17M0.17M0.11M0.08M0.06M-0.25M
Interest & Investment Income (Quarter)
253.00636.00802.000.00M0.00M0.00M0.01M0.00M0.01M
Other Non Operating Income (Quarter)
0.00M0.00M0.07M-0.90M
Non Operating Income (Quarter)
0.00M-0.02M0.02M0.06M0.14M0.12M0.18M0.17M0.17M0.11M0.08M0.06M0.03M0.01M-0.07M-0.03M-1.38M
Net income details
EBT (Quarter)
-2.02M-2.33M-3.78M-2.55M-1.97M-2.49M-2.40M-3.47M-2.30M-1.81M-2.65M-3.24M-2.61M-2.53M-1.20M-9.49M-2.38M-3.67M-3.19M-2.76M
Tax Provisions (Quarter)
-0.05M
Profit After Tax (Quarter)
373.00-2.25M-7.50M-0.04M-1.97M-2.45M-2.33M6.51M-2.17M-1.60M-2.45M-3.07M-2.48M-2.43M-1.15M-3.78M-2.37M-3.22M-3.10M-4.09M
Income from Continuing Operations (Quarter)
-2.02M-2.33M-3.78M-2.55M-1.92M-2.49M-2.40M-3.47M-2.30M-1.81M-2.65M-3.24M-2.61M-2.53M-1.20M-9.49M-2.38M-3.67M-3.19M-2.76M
Consolidated Net Income (Quarter)
-2.02M-2.33M-3.78M-2.55M-1.92M-2.49M-2.40M-3.47M-2.30M-1.81M-2.65M-3.24M-2.61M-2.53M-1.20M-9.49M-2.38M-3.67M-3.19M-2.76M
Income towards Parent Company (Quarter)
-2.02M-2.33M-3.78M-2.55M-1.92M-2.49M-2.40M-3.47M-2.30M-1.81M-2.65M-3.24M-2.61M-2.53M-1.20M-9.49M-2.38M-3.67M-3.19M-2.76M
Net Income towards Common Stockholders (Quarter)
-2.02M-2.33M-3.78M-2.55M-1.92M-2.49M-2.40M-3.47M-2.30M-1.81M-2.65M-3.24M-2.61M-2.53M-1.20M-9.49M-2.38M-3.67M-3.19M-2.76M
Additional items
EPS (Basic) (Quarter)
-32.04-27.19-0.05-0.02-12.27-15.85-15.16-22.05-14.51-11.39-16.15-19.70-14.67-14.12-23.98-186.99-46.92-10.72-9.84-5.09
EPS (Diluted) (Quarter)
-158.84-183.39-298.02-201.02-151.54-196.45-189.05-273.52-181.48-142.47-16.15-19.70-14.67-14.12-6.71-53.00-13.06-19.21-12.18-8.05
Shares Outstanding (Quarter)
0.06M0.09M69.17M112.75M0.16M0.16M0.16M0.16M0.16M0.16M0.16M0.16M0.18M0.18M0.05M0.05M0.05M0.34M0.32M0.54M
Shares Outstanding (Diluted) (Quarter)
0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.16M0.16M0.18M0.18M0.18M0.18M0.18M0.19M0.26M0.34M
Shares Outstanding (Entity) (Quarter)
0.06M0.09M69.17M112.75M0.16M0.16M0.16M0.16M0.16M0.16M0.18M0.18M0.18M0.18M0.05M0.05M0.05M0.34M0.32M0.54M
EBITDA (Quarter)
-1.87M-2.25M-3.78M-2.55M-1.95M-2.47M-2.39M-3.48M-2.29M-1.78M-2.61M-3.24M-2.59M-2.51M-1.20M-3.81M-2.38M-3.15M-3.09M-2.79M
Interest Expenses (Quarter)
0.15M0.08M0.02M0.02M0.01M-0.01M0.01M0.02M0.03M0.02M0.02M0.01M5.68M0.01M0.53M0.11M-0.03M
Tax Rate (Quarter)
2.34%